

Paul Grootendorst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8128052/publications.pdf>

Version: 2024-02-01

71
papers

2,779
citations

331670

21
h-index

182427

51
g-index

73
all docs

73
docs citations

73
times ranked

4247
citing authors

#	ARTICLE	IF	CITATIONS
1	Brand drug companies impeding generic drug company access to product samples: Estimated prevalence and impact on drug costs. <i>Journal of Generic Medicines</i> , 2022, 18, 10-20.	0.2	1
2	The effect of patented drug price on the share of new medicines across OECD countries. <i>Health Policy</i> , 2022, 126, 795-801.	3.0	1
3	Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β -amyloid peptide accumulation in mice. <i>Biopharmaceutics and Drug Disposition</i> , 2021, 42, 372-388.	1.9	6
4	Impact of a peer comparison intervention on seasonal influenza vaccine uptake in community pharmacy: A national cluster randomized study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, 539-546.e5.	1.5	0
5	The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. <i>Liver International</i> , 2020, 40, 51-59.	3.9	6
6	Development and Validation of a Clinical Prediction Tool for Seasonal Influenza Vaccination in England. <i>JAMA Network Open</i> , 2020, 3, e207743.	5.9	2
7	Factors associated with drug shortages in Canada: a retrospective cohort study. <i>CMAJ Open</i> , 2020, 8, E535-E544.	2.4	13
8	Patient and practice level factors associated with seasonal influenza vaccine uptake among at-risk adults in England, 2011 to 2016: An age-stratified retrospective cohort study. <i>Vaccine: X</i> , 2020, 4, 100054.	2.1	35
9	The Impact of Tiered-Pricing Framework on Generic Entry in Canada. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	2
10	Estimating the clinical cost of drug development for orphan versus non-orphan drugs. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 12.	2.7	68
11	Pharmacists should counsel users of medical cannabis, but should they be dispensing it?. <i>Canadian Pharmacists Journal</i> , 2019, 152, 10-13.	0.8	6
12	Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. <i>BMJ Open</i> , 2019, 9, e027491.	1.9	23
13	Medicine Prices in the United States and Canada. , 2019, , 31-43.		0
14	Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. <i>International Journal of Health Services</i> , 2018, 48, 702-715.	2.5	2
15	Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study. <i>PLoS ONE</i> , 2018, 13, e0195185.	2.5	7
16	Uptake and impact of regulated pharmacy technicians in Ontario community pharmacies. <i>Canadian Pharmacists Journal</i> , 2018, 151, 197-202.	0.8	4
17	Policy to encourage the development of antimicrobials. <i>International Journal of Health Governance</i> , 2018, 23, 101-110.	1.2	2
18	Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. <i>Pharmacoeconomics - Open</i> , 2017, 1, 167-173.	1.8	4

#	ARTICLE	IF	CITATIONS
19	A comparison of mechanisms for setting generic drug prices in Canada. <i>Journal of Generic Medicines</i> , 2017, 13, 19-27.	0.2	6
20	Does rising income inequality affect mortality rates in advanced economies?. <i>Economics</i> , 2017, 11, .	0.6	0
21	Factors associated with mental health in Canadian Veterans. <i>Journal of Military, Veteran and Family Health</i> , 2017, 3, 41-51.	0.6	9
22	Clinical and microbiological epidemiology of early and late infectious complications among solid-organ transplant recipients requiring hospitalization. <i>Transplant International</i> , 2016, 29, 1029-1038.	1.6	18
23	The case for an essential medicines list for Canada. <i>Cmaj</i> , 2016, 188, E499-E503.	2.0	15
24	Economic evaluation of vaccines in Canada: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1257-1264.	3.3	8
25	How Effective Is the Medicare Part D Drug Plan?. <i>Annals of Internal Medicine</i> , 2015, 162, 869-870.	3.9	1
26	The Opportunity Cost of Capital. <i>Inquiry (United States)</i> , 2015, 52, 004695801558464.	0.9	8
27	Determinants of chronic physical health conditions in Canadian Veterans. <i>Journal of Military, Veteran and Family Health</i> , 2015, 1, 32-42.	0.6	5
28	Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics. <i>International Journal of the Economics of Business</i> , 2015, 22, 201-217.	1.7	6
29	Intended and unintended effects of restrictions on the sale of cigarillos to youth: evidence from Canada. <i>Tobacco Control</i> , 2015, 24, 382-388.	3.2	6
30	Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments. <i>Annals of Emergency Medicine</i> , 2015, 66, 455-463.e4.	0.6	16
31	Validation of Six Short and Ultra-short Screening Instruments for Depression for People Living with HIV in Ontario: Results from the Ontario HIV Treatment Network Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0142706.	2.5	23
32	Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem. <i>Healthcare Policy</i> , 2015, 11, 10-4.	0.6	4
33	Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada. <i>Applied Economics</i> , 2014, 46, 1081-1092.	2.2	10
34	Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis. <i>CMAJ Open</i> , 2013, 1, E83-E90.	2.4	12
35	Effect of the Low Risk Ankle Rule on the frequency of radiography in children with ankle injuries. <i>Cmaj</i> , 2013, 185, E731-E738.	2.0	41
36	Canada's laws on pharmaceutical intellectual property: the case for fundamental reform: Figure 1:. <i>Cmaj</i> , 2012, 184, 543-549.	2.0	8

#	ARTICLE	IF	CITATIONS
37	The cost of drug development: A systematic review. <i>Health Policy</i> , 2011, 100, 4-17.	3.0	379
38	Equity in dental care among Canadian households. <i>International Journal for Equity in Health</i> , 2011, 10, 14.	3.5	30
39	Economic instruments for obesity prevention: results of a scoping review and modified delphi survey. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2011, 8, 109.	4.6	57
40	Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 838-848.	1.9	27
41	New approaches to rewarding pharmaceutical innovation. <i>Cmaj</i> , 2011, 183, 681-685.	2.0	32
42	How should we support pharmaceutical innovation?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 313-320.	1.4	5
43	Response to Lichtenberg. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 505-508.	1.4	0
44	Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 353-364.	1.4	23
45	Validation of a Prediction Model to Estimate Health Utilities Index Mark 3 Utility Scores from WOMAC Index Scores in Patients with Osteoarthritis of the Hip. <i>Value in Health</i> , 2008, 11, 470-477.	0.3	21
46	The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada. <i>Health Policy</i> , 2007, 84, 1-13.	3.0	5
47	The Effect of Pharmaceutical Patent Term Length on Research and Development and Drug Expenditures in Canada. <i>Healthcare Policy</i> , 2007, 2, 63-84.	0.6	6
48	Becoming the best mom that I can: women's experiences of managing depression during pregnancy – a qualitative study. <i>BMC Women's Health</i> , 2007, 7, 13.	2.0	27
49	A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. <i>Statistics in Medicine</i> , 2007, 26, 734-753.	1.6	940
50	Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. <i>Statistics in Medicine</i> , 2007, 26, 754-768.	1.6	185
51	A review of instrumental variables estimation of treatment effects in the applied health sciences. <i>Health Services and Outcomes Research Methodology</i> , 2007, 7, 159-179.	1.8	37
52	Response to Pazderka and Schroeder. <i>Healthcare Policy</i> , 2007, 2, 95-96.	0.6	0
53	Response to pazderka and schroeder. <i>Healthcare Policy</i> , 2007, 2, 95-6.	0.6	0
54	The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada. <i>Healthcare Policy</i> , 2007, 2, 63-84.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Dental insurance, income and the use of dental care in Canada. <i>Journal of the Canadian Dental Association</i> , 2007, 73, 57.	0.6	54
56	A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. <i>Journal of Rheumatology</i> , 2007, 34, 534-42.	2.0	42
57	A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. <i>Health Economics (United Kingdom)</i> , 2006, 15, 735-742.	1.7	23
58	Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis. <i>Journal of Health Services Research and Policy</i> , 2006, 11, 13-20.	1.7	20
59	Distributional effects of 'general population' prescription drug programs in Canada. <i>Canadian Journal of Economics</i> , 2005, 38, 128-148.	1.2	13
60	Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. <i>Health Economics (United Kingdom)</i> , 2005, 14, 909-923.	1.7	59
61	Disclosure of Physician Prescribing Information and Prescription Drug Costs: Evidence from Saskatchewan. <i>Journal of Pharmaceutical Marketing and Management</i> , 2005, 17, 61-87.	0.1	1
62	The Economics of Cross-Border Trade in Pharmaceuticals. <i>Journal of Pharmaceutical Marketing and Management</i> , 2005, 16, 99-109.	0.1	1
63	Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence. <i>International Journal of Health Services</i> , 2004, 34, 101-122.	2.5	160
64	The Economics of Cross-Border Trade in Pharmaceuticals: Theory and Evidence. <i>Journal of Pharmaceutical Marketing and Management</i> , 2004, 16, 99-109.	0.1	1
65	An empirical analysis of milk addiction. <i>Journal of Health Economics</i> , 2004, 23, 1117-1133.	2.7	118
66	Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents. <i>Medical Care</i> , 2004, 42, 653-660.	2.4	44
67	A Review of the Comprehensiveness of Provincial Drug Coverage for Canadian Seniors. <i>Canadian Journal on Aging</i> , 2003, 22, 33-44.	1.1	5
68	Validity of self-reported prescription drug insurance coverage. <i>Health Reports</i> , 2003, 14, 35-46.	0.8	6
69	The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada. <i>Journal of Health Economics</i> , 2002, 21, 805-826.	2.7	21
70	On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. <i>Health Policy</i> , 2001, 55, 97-109.	3.0	32
71	Censoring in statistical models of health status: what happens when one can do better than '1'. , 2000, 9, 911-914.		19